ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - July 1959

Decade

Year

Issue

December 2021, Vol 78, No. 12, Pages 1429-1533

Viewpoint

Practical Advice on Surviving and Thriving as an Academic Physician-Neuroscientist

Abstract Full Text
JAMA Neurol. 2021;78(12):1439-1440. doi:10.1001/jamaneurol.2021.3889

This Viewpoint describes ways to assist graduates of MD-PhD programs in advancing their careers and reduce the rate of attrition among these physician-scientists.

On the Brain

Full Circle

Abstract Full Text
JAMA Neurol. 2021;78(12):1441-1442. doi:10.1001/jamaneurol.2021.3909

This essay describes the author’s experience of developing autoimmune encephalitis during her third year of residency and being a physician who has also been a patient.

Editorial

Citius, Fortius, Altius—Understanding Which Components Drive Exercise Benefits in Parkinson Disease

Abstract Full Text
JAMA Neurol. 2021;78(12):1443-1445. doi:10.1001/jamaneurol.2021.3744
Original Investigation

Association of Physical Activity, Including Amount and Maintenance, With All-Cause Mortality in Parkinson Disease

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1446-1453. doi:10.1001/jamaneurol.2021.3926

This cohort study uses a national sample of Korean individuals with Parkinson disease to evaluate associations between physical activity, including amount and maintenance, and mortality.

Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial

Abstract Full Text
free access has active quiz
JAMA Neurol. 2021;78(12):1454-1460. doi:10.1001/jamaneurol.2021.3828

This post hoc analysis evaluates whether anticoagulation is superior to aspirin in reducing recurrent stroke in patients with embolic stroke of undetermined source and left ventricular dysfunction.

Long-term Risk of Parkinson Disease Following Influenza and Other Infections

Abstract Full Text
free access has active quiz
JAMA Neurol. 2021;78(12):1461-1470. doi:10.1001/jamaneurol.2021.3895

This case-control study examines whether prior influenza and other infections are associated with Parkinson disease more than 10 years after infection using data from 1977 to 2016 from the Danish National Patient Registry.

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Abstract Full Text
open access
JAMA Neurol. 2021;78(12):1471-1483. doi:10.1001/jamaneurol.2021.3671

This cross-sectional cohort study evaluates plasma glial fibrillary acidic protein levels throughout the entire Alzheimer disease continuum, from preclinical Alzheimer disease to Alzheimer disease dementia, compared with cerebrospinal fluid glial fibrillary acidic protein.

Association Between Increased Seizures During Rewarming After Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy and Abnormal Neurodevelopmental Outcomes at 2-Year Follow-up: A Nested Multisite Cohort Study

Abstract Full Text
free access has audio
JAMA Neurol. 2021;78(12):1484-1493. doi:10.1001/jamaneurol.2021.3723

This cohort study evaluates whether electrographic seizures are more likely to occur during rewarming compared with the preceding period and whether they are associated with abnormal outcomes in asphyxiated neonates receiving hypothermia therapy.

Association of White Matter Hyperintensities With Pathology and Progression of Parkinsonism in Aging

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1494-1502. doi:10.1001/jamaneurol.2021.3996

This cohort study examines if the burden of cerebral white matter hyperintensity is associated with the rate of progressive parkinsonism among older adults.

Brief Report

Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms

Abstract Full Text
open access
JAMA Neurol. 2021;78(12):1503-1509. doi:10.1001/jamaneurol.2021.3821

This case series examines whether anti–SARS-CoV-2 and autoreactive antibodies are present in the cerebrospinal fluid (CSF) of pediatric patients with COVID-19 and subacute neuropsychiatric dysfunction.

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1510-1514. doi:10.1001/jamaneurol.2021.3599

This cohort study assesses the potential association of ocrelizumab, a B-cell–depleting agent, with the T-cell and antibody SARS-CoV-2 response following vaccination with the messenger RNA vaccine BNT162b2 in patients with multiple sclerosis.

Review

Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US: A Review

Abstract Full Text
JAMA Neurol. 2021;78(12):1515-1524. doi:10.1001/jamaneurol.2021.3416

This narrative review provides a contemporary synthesis of evidence examining health disparities, inequities, and social determinants of health in US Black and Hispanic or Latinx patients with multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody disorders.

Research Letter

Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1525-1527. doi:10.1001/jamaneurol.2021.3589

This study investigates the longitudinal course of blood-based biomarkers representing the brain parenchyma in long-duration spaceflight.

Targeting Vascular Risk Factors to Reduce Dementia Incidence in Old Age: Extended Follow-up of the Prevention of Dementia by Intensive Vascular Care (preDIVA) Randomized Clinical Trial

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1527-1528. doi:10.1001/jamaneurol.2021.3542

This follow-up analysis of a randomized clinical trial investigates the association of multidomain interventions targeting vascular risk factors with dementia incidence among community-dwelling older adults.

Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1529-1531. doi:10.1001/jamaneurol.2021.3609

This cohort study investigates the humoral response to 2 SARS-CoV-2 messenger RNA vaccines in patients with multiple sclerosis treated with fingolimod and ocrelizumab.

Visual Neglect After an Isolated Lesion of the Superior Colliculus

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1531-1533. doi:10.1001/jamaneurol.2021.3863

This case report describes an otherwise healthy young woman with a small abscess confined to the right superior colliculus.

Correction

Title Updated

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1533. doi:10.1001/jamaneurol.2021.4621
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2021;78(12):1429. doi:10.1001/jamaneurol.2020.3703
×